These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9355894

  • 1. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.
    Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires JA, Kobrin I.
    Circulation; 1997 Oct 21; 96(8):2557-64. PubMed ID: 9355894
    [Abstract] [Full Text] [Related]

  • 2. Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
    Davies GJ, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):34C-39C. PubMed ID: 9286852
    [Abstract] [Full Text] [Related]

  • 3. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS, Bakx AL, Braun S, Frishman WH, Schneeweiss A, Tzivoni D, Kobrin I.
    Am J Cardiol; 1997 Aug 21; 80(4B):20C-26C. PubMed ID: 9286850
    [Abstract] [Full Text] [Related]

  • 4. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
    Frishman WH, Bittar N, Glasser S, Habib G, Smith W, Pordy R.
    Clin Cardiol; 1998 Jul 21; 21(7):483-90. PubMed ID: 9669057
    [Abstract] [Full Text] [Related]

  • 5. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S, van der Wall EE, Emanuelsson H, Kobrin I.
    J Am Coll Cardiol; 1996 Feb 21; 27(2):317-22. PubMed ID: 8557900
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I, Bieska G, Charlon V, Lindberg E, Pordy R.
    Cardiology; 1998 Feb 21; 89 Suppl 1():23-32. PubMed ID: 9570426
    [Abstract] [Full Text] [Related]

  • 8. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG.
    Angiology; 1999 Jun 21; 50(6):447-54. PubMed ID: 10378820
    [Abstract] [Full Text] [Related]

  • 9. Differential properties of mibefradil in hypertension and angina.
    Kobrin I.
    J Hypertens Suppl; 1997 Dec 21; 15(5):S33-40. PubMed ID: 9481614
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
    Cleophas TJ, van der Sluijs J, van der Vring JA, Daniëls MC, Holwerda KJ, Withagen AJ, Schelling A, Hendriks MG, Zwinderman AH.
    J Clin Pharmacol; 1999 Jul 21; 39(7):738-46. PubMed ID: 10392329
    [Abstract] [Full Text] [Related]

  • 12. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA, Daniëls MC, Holwerda NJ, Withagen PJ, Schelling A, Cleophas TJ, Hendriks MG.
    Br J Clin Pharmacol; 1999 May 21; 47(5):493-8. PubMed ID: 10336572
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A, Kobrin I, Charlon V, Caspi A, Marmor A, Sclarovsky S, Reisin L, Schlesinger Z.
    Am Heart J; 1998 Feb 21; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris.
    Steffensen R, Melchior T, Bech J, Nissen H, Haastrup B, Grande P, Rasmussen V, Hansen JF, Skagen K, Haghfelt T.
    Cardiovasc Drugs Ther; 1997 Nov 21; 11(5):629-35. PubMed ID: 9493700
    [Abstract] [Full Text] [Related]

  • 17. Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.
    Davies GJ, Kobrin I, Caspi A, Reisin LH, de Albuquerque DC, Armagnijan D, Coelho OR, Schneeweiss A.
    Am Heart J; 1997 Aug 21; 134(2 Pt 1):220-8. PubMed ID: 9313601
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN, Markham A.
    Drugs; 1997 Nov 21; 54(5):774-93. PubMed ID: 9360062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.